COMPETITIVE ABILITY OF MAIZE IN MIXTURE WITH CLIMBING BEAN IN ORGANIC FARMING

Intercropped crops represent an important production system in organic farming, especially maize/climbing bean mixture due to its high content of protein in bean seeds for human diet, and producing silage for ruminants. To test this hypothesis, the effects of maize (Zea mays L.) sown as a sole crop and maize/climbing bean (Phaseolus vulgaris L. cv. Cipro) mixtures on maize plant height, maize leaf area index, bean leaf area index and grain yield were investigated in field experiments on an organic farm following accepted rules of certification. The maize/climbing bean mixture increased maize plant height as well as maize and bean leaf area and reduced maize grain yield in comparison with maize sown as sole crop, but 477.5 kg ha-1seed yield of bean sown in mixture was obtained. Maize was a stronger competitor than bean. The overall conclusion is that maize/bean mixture has promise for producing valuable yield of maize and bean, but mixtures needs further investigation

Az ökológiai gazdálkodás hazai helyzete - Trendek és kitörési pontok |Program|Összefoglalók|Résztvevők|

A kiadvány az ÖMKi 2012. február 2-án megrendezett első szakmai konferenciájának programját és előadásainak anyagát tartalmazza. Az ökológiai gazdálkodás hazai helyzete - Trendek és kitörési pontok c. rendezvényt minden várakozást felülmúló érdeklődés övezte, több mint 400-an regisztráltak. A rendezvény fővédnöke Fazekas Sándor vidékfejlesztési miniszter volt, aki megnyitó beszédében elmondta: „Háromszázezer hektárra szeretnénk növelni hazánkban a biogazdálkodás alá vont területek nagyságát 2020-ig, ezért a tárca ökológiai mezőgazdálkodási programot dolgoz ki. Kiemelten támogatjuk a biogazdálkodókat, segítséget nyújtunk az átálláshoz”. A konferencián jelen voltak az ágazat legfontosabb szervezeteinek képviselői, úgy a gazdák, a civil társadalom, mint a közigazgatás és a tudomány világából. Értékes párbeszéd alakult ki a résztvevők között, és lehetőség nyílt a vélemények ütköztetésére is, amit szervezőként kifejezetten hasznosnak tartunk, hiszen hozzátartozik az átlátható, demokratikus biomozgalom megteremtéséhez

The knowledge transfer from science to practice – a survey with EU researchers

Group members came from 12 European countries, six from new (Bulgaria, Czech Republic, Estonia, Hungary, Poland and Slovenia) and six from old EU member states (Germany, Spain, Finland, Italy, The Netherlands, Portugal). The aim of the work was to analyze the role of the scientists in a dialogue between them and the practitioners within the organic production sector. Another important aim was to find the best practice models of such dialogue as the examples to be followed by others. In order to reach this aim the survey with the scientists has been conducted by all project partners; every partner has conducted the survey with 10 selected scientists from own country. Only the scientists possessing PhD level and actively working in the organic sector could be selected. Key areas of the questionnaire were directed to the (A) person (gender, age, years of activity in teaching and/or researching), (B) number of projects, papers, trainings and interviews, (C) Examples of best practice models, (D) Estimations of potential collaboration and dialog between scientists and stakeholders, (E) Estimations about the success of personal activities with regard to the improvement of the four fields (farming, processing, trading & marketing), (F) Estimates of the improvement of communication and knowledge transfer from science to practice, (G) Estimates of potential threats for good communication and knowledge transfer among scientists and practitioners. Interviewees were finally asked for general remarks and comments. The results indicate that there is not a big difference between the scientists from the old EU member states and new EU member states in most of the analyzed areas. The main difference is that the scientists from the new EU member states provide more training sessions for practitioners outside their institutions compared to the researchers from the old EU member states. The results reveal also a relatively low level of the researchers’ activity in conducting the implementation projects and writing the popular papers, both in the old and new EU member states

Professional training in organic food production: a cross-country experience

Purpose: The aim of this work was to characterize the agricultural activities and past experience in professional training in the context of mobile learning in different countries (Portugal, Spain, Slovakia, Hungary, United Kingdom, Italy and Turkey). Design: For the survey, a questionnaire was prepared in English and Portuguese and then translated into the languages of the participating countries. It was delivered electronically for answering on-line by adults only. The participation was voluntary and in the end 133 consented valid questionnaires were obtained. For the treatment of the data was used SPSS and basic descriptive statistics tools were applied, together with tests, namely crosstabs and chi square tests, considering a level of significance of 5%. Findings: The results showed that the majority of the participants presently have some agricultural activity and one third is thinking about starting one the future. Most of the participants want to produce food in organic mode, with significant differences among the countries at study. Most of the participants were enrolled in training activities in agriculture, especially those with higher education. This participation showed significant differences between countries and also according to the dimension of the farms owned by the participants. A significant association was found between being a teacher in forming activities related to agriculture and being a farmer. When compared to distance learning, the training activities in classroom were the most frequented, with significant differences among the countries. Practical implications: This study allowed characterizing the learning activities in the field of organic agriculture and establish direction lines for planning of future training programs, in different countries, with maybe different social, educational and cultural realities Originality/value: Because the study included the participation of people from several countries all around Europe, the results obtained enrich the scientific area of training in Organic Farming, in view of distance learning versus classroom learning on a more global basis.info:eu-repo/semantics/publishedVersio

Severe early onset preeclampsia: short and long term clinical, psychosocial and biochemical aspects

Preeclampsia is a pregnancy specific disorder commonly defined as de novo hypertension and proteinuria after 20 weeks gestational age. It occurs in approximately 3-5% of pregnancies and it is still a major cause of both foetal and maternal morbidity and mortality worldwide1. As extensive research has not yet elucidated the aetiology of preeclampsia, there are no rational preventive or therapeutic interventions available. The only rational treatment is delivery, which benefits the mother but is not in the interest of the foetus, if remote from term. Early onset preeclampsia (<32 weeks’ gestational age) occurs in less than 1% of pregnancies. It is, however often associated with maternal morbidity as the risk of progression to severe maternal disease is inversely related with gestational age at onset2. Resulting prematurity is therefore the main cause of neonatal mortality and morbidity in patients with severe preeclampsia3. Although the discussion is ongoing, perinatal survival is suggested to be increased in patients with preterm preeclampsia by expectant, non-interventional management. This temporising treatment option to lengthen pregnancy includes the use of antihypertensive medication to control hypertension, magnesium sulphate to prevent eclampsia and corticosteroids to enhance foetal lung maturity4. With optimal maternal haemodynamic status and reassuring foetal condition this results on average in an extension of 2 weeks. Prolongation of these pregnancies is a great challenge for clinicians to balance between potential maternal risks on one the eve hand and possible foetal benefits on the other. Clinical controversies regarding prolongation of preterm preeclamptic pregnancies still exist – also taking into account that preeclampsia is the leading cause of maternal mortality in the Netherlands5 - a debate which is even more pronounced in very preterm pregnancies with questionable foetal viability6-9. Do maternal risks of prolongation of these very early pregnancies outweigh the chances of neonatal survival? Counselling of women with very early onset preeclampsia not only comprises of knowledge of the outcome of those particular pregnancies, but also knowledge of outcomes of future pregnancies of these women is of major clinical importance. This thesis opens with a review of the literature on identifiable risk factors of preeclampsia

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

CMS physics technical design report : Addendum on high density QCD with heavy ions

Peer reviewe

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. CONCLUSION: The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT01090362